Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3052 | Powered Air purifying respirator Wiki | 1.00 |
| drug2981 | Placebo oral tablet Wiki | 0.18 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Description: The ordinal scale is an evaluation of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Measure: The proportion of patients with a two-point change using the 8-category ordinal scale Time: Day 14 from baselineDescription: All-cause mortality post baseline
Measure: All-Cause mortality Time: Day 28 and Day 60 post baselineDescription: Time to a 2-point clinical change difference
Measure: Time to a 2-point clinical change Time: Up to 60 days post baselineDescription: Duration of hospitalization
Measure: Hospitalization Time: Up to 60 days post baselineDescription: For subjects who are on ECMO or mechanical ventilation at Day 1
Measure: Duration of ECMO or invasive mechanical ventilation Time: Up to 60 days post baselineDescription: For subjects who are in ICU at Day 1
Measure: Duration of ICU stay Time: Up to 60 days post baselineDescription: Time to SARS-CoV-2 negative by reverse transcriptase-polymerase chain reaction (RT-PCR)
Measure: SARS-CoV-2 negative Time: Up to 60 days post baselineDescription: Proportion of patients with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT PCR on days 5, 10, 14, 21, and 28 after starting treatment
Measure: Negative oropharyngeal or nasopharyngeal swab Time: Up to 28 days post baselineDescription: Proportion of subjects with serious adverse events
Measure: Serious adverse events (SAEs) Time: Up to 60 days post baselineDescription: Proportion of subjects who discontinue study drug due to adverse events
Measure: Discontinuation due to adverse events Time: Up to 60 days post baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports